MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Cidara Therapeutics Net Income 2011-2025 | CDTX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Cidara Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -170 M | -22.9 M | -33.6 M | -42.5 M | -72.1 M | -41.1 M | -59 M | -55.7 M | -48.2 M | -32.2 M | -11.9 M | -1.34 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.34 M | -170 M | -49.2 M |
Quarterly Net Income Cidara Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -83.2 M | -25.7 M | -23.5 M | - | -16 M | -91.2 M | -10.3 M | - | -9.11 M | -13.6 M | 3.01 M | - | 15 M | -13.1 M | -18.3 M | - | -18.1 M | 10.7 M | -18.3 M | - | -17.6 M | -18.3 M | -14.5 M | -14 M | 3.04 M | -13.5 M | -16.6 M | -12.3 M | -13.6 M | -16.3 M | -16.7 M | -13.4 M | -12.3 M | -16.6 M | -13.4 M | -14.4 M | -12.2 M | -11.8 M | -9.79 M | -9.87 M | -9.17 M | -6.41 M | -6.74 M | -4.65 M | -3.32 M | -3.22 M | -707 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15 M | -91.2 M | -14.5 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
-72.8 M | $ 4.79 | 2.35 % | $ 795 M |  Canada |
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-208 M | - | - | $ 1.01 B |  USA |
 |
Aclaris Therapeutics
ACRS
|
-132 M | $ 3.04 | 4.83 % | $ 235 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-58.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.63 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
-24.1 M | $ 0.93 | -8.81 % | $ 257 K | USA |
 |
Athersys
ATHX
|
-87 M | - | 3.77 % | $ 22.4 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Avenue Therapeutics
ATXI
|
-11.7 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
12.2 M | - | 1083.1 % | $ 745 M | USA |
 |
BioDelivery Sciences International
BDSI
|
84.9 M | - | -4.8 % | $ 255 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-384 M | $ 212.81 | 1.71 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-645 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioVie
BIVI
|
-17.5 M | $ 1.27 | -3.05 % | $ 1.88 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.8 M | $ 3.1 | 0.16 % | $ 7.46 B |  Australia |
 |
Bellicum Pharmaceuticals
BLCM
|
-25 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-98 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
-212 M | - | - | $ 546 M | USA |
 |
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | USA |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 12.37 | 2.06 % | $ 814 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-433 M | - | - | $ 7.29 B | USA |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M |  France |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Celldex Therapeutics
CLDX
|
-158 M | $ 26.83 | 0.94 % | $ 1.73 M | USA |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-114 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Celsion Corporation
CLSN
|
-18.6 M | - | -6.63 % | $ 13.9 M | USA |
 |
BioNTech SE
BNTX
|
10.3 B | $ 95.03 | 0.95 % | $ 27.2 B | Germany |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
160 M | $ 26.81 | 1.36 % | $ 1.3 B | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
141 M | $ 83.59 | 1.95 % | $ 8.63 B | USA |
 |
Anika Therapeutics
ANIK
|
-82.7 M | $ 9.48 | 0.96 % | $ 139 M | USA |
 |
CorMedix
CRMD
|
-46.3 M | $ 12.19 | 1.75 % | $ 621 M | USA |
 |
Cortexyme
CRTX
|
-31.4 M | - | -1.05 % | $ 67.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.88 M | $ 0.18 | -25.03 % | $ 392 M |  Israel |
 |
CTI BioPharma Corp.
CTIC
|
-93 M | - | - | $ 1.2 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
-616 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
377 M | $ 591.15 | 0.02 % | $ 44.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.53 | -0.39 % | $ 15.9 M | USA |
 |
AstraZeneca PLC
AZN
|
115 M | $ 92.45 | 0.34 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-5.69 M | - | -5.38 % | $ 6.06 M | USA |